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Letter of Report Submission 
YBhg. Profesor Dr. Hadariah Bahron 
Assistant Vice Chancellor (Research & Innovation) 
Research Management Institute (RMI) 
Universiti Teknologi MARA (UiTM) 
40450 Shah Alam 
Selangor Darul Ehsan 
Dear Professor Dr. Hadariah Bahron, 
Submission of Final Report for MAKNA Grant 
Herewith we are submitting the final report for the MAKNA Grant entitled 
"Synergistic Effects of Cisplatin and Apigenin on Telomerase Expression and 
Telomerase Activity in TNBC cells " with the project code number 100-RMI/PRI 
16/6/2 (6/2013) under the basic medical sciences category. The grant was awarded 
to Noorfaiza binti A. Aziz with a total amount of RM30.000.00. 
Here we are reporting the synergistic 
expression and activity of the reverse transcriptase 
for the viability of two triple negative breast 
cell line. 
All researchers have seen and agreed with 
the Research Management Institute (RMI) pf UiTM for supporting our research in the 
field of breast cancer and natural products. 
Thank you. 
pffect of apigenin and cisplatin on the 
telomerase and its consequence 
cancer and one non-tumorigenic epithelial 
the content of this report. Lastly, we thank 
Best regards, 
Associate Professor Dr Gabriele Ruth Anisdih Froemming 
Project Leader 
Institute of Pathology, Laboratory and Forensic Medicine (1-PPerForM) 
Faculty of Medicine 
Universiti Teknologi MARA 
Jalan Hospital 
47000, Sungai Buloh 
Selangor 
and 
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3.2 Enhanced Executive Summary 
Two 
(MCF-
Almost 80-90% of cancer cells show a 
differentiated cells have no or very little 
depends on several factors like increased 
telomerase structural subunits and telomere 
for triple negative breast cancer (TNBC) 
Therefore, in this work, the effect of apigenfn 
activity and structure was investigated 
and HCC1806) and one control cell line 
the cytotoxicity of the compounds 
translational level of active telomerase i 
measured using RT-PCR and ELISA. The 
and its activity highly depended on the 
telomerase activity in TNBC cells by cisp 
reduction of Hsp90 and p23 levels. The 
inhibited Hsp90 expression in MCF-10A 
detected in p23 expression as compared 
expression in TNBC was inhibited after 
apigenin. No significant changes were 
treatment in HCC1806. In MDA-MB-231 
increase in p53 protein expression as co 
was up-regulated at the higher concentration 
treatment in MCF-10A cells. In conclusion 
apigenin telomerase activity in TNBC 
Nevertheless, telomerase activity remain^ 
TNBC, and the combination of cisplatin 
cancer cells but unfortunately less protectivb 
highly active telomerase while normal, 
activity. Telomerase activity in cancer cells 
hTERT expression, modification of 
-associated proteins. Treatment options 
limited due to a lack of possible targets. 
i with and without cisplatin on telomerase 
different types of TNBC (MDA-MB-231 
10A) were evaluated with regards to 
mebtioned above. The transcriptional and 
including hTERT, Hsp90, p23 and p53 were 
gene and protein expression of telomerase 
cell type investigated. The reduction of 
atin and apigenin was associated with a 
cofnbined treatment of cisplatin and apigenin 
However, no significant change was 
to control cells. The level of p53 protein 
the combined treatment of cisplatin and 
observed after cisplatin and apigenin single 
displatin-treated cells showed a significant 
rppared to control. The expression of p53 
of cisplatin as well as the combined 
, the inhibitory effect of cisplatin and 
inlvolves complex regulatory mechanisms. 
a potential target for the treatment of 
£nd apigenin offers increased efficacy in 
in normal cells. 
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3.3 Introduction 
Triple Negative Breast Cancer (TNBC) i 
breast cancer form with a low five-year suifvival 
is negative for the expression of estrogejn 
receptors it has limited treatment options 
heterogeneity of deregulated pathways, 
cancers have been developed including 
radiotherapy, hormonal therapy or targeted 
approach whereby two or more pathways 
a highly heterogeneous and metastatic 
rate of diagnosed patients. As TNBC 
(ER), progesterone (PR) and Her2neu 
due to a lack of molecular targets and the 
yarious therapeutic treatments for breast 
surgery, adjuvant chemotherapy, 
therapy. Combination therapy is a new 
targeted at the same time. are 
luig 
Cisplatin belongs to the class of platinum 
to treat various types of cancer including 
and lymphoma. However, the usage of this 
many side effects to normal cells. Cisplatin 
binding to genomic and non-DNA targets 
DNA replication that leads to the activation 
al., 2007). Another limiting factor is the 
after prolonged treatment, or in re-
decrease cisplatin toxicity in normal cells 
without triggering the development of ci 
for the treatment of TNBC. 
containing anticancer drugs which is used 
cancer, ovarian cancer, germ cell tumor 
drug is reduced due to its high toxicity and 
induces cytotoxicity in tumour cells by 
and therefore inhibiting transcription and 
of either necrosis or apoptosis (Cepeda et 
development of cisplatin-resistant cancer cells 
emerging cancer. Any compound that can 
while increasing its toxicity in cancer cells 
isplntin resistance would be of immense value 
Various natural products or bioactive corripounds 
have shown potential anticarcinogenic abilities 
cells. Apigenin (4', 5, 7-trihydroxyflavone) 
flavonoids that are commonly found in 
Previous investigations have reported that 
and free-radical scavenging properties 
Romanova et al., 2001). 
V 
One of the characteristics of malignant 
transcriptase telomerase. Shay et al. (1997) have reported that 85 - 90 percent of all 
cancer cells have telomerase activity while 
isolated from various plant parts 
in inhibiting the progression of cancer 
is a flavone and belongs to the group of 
and vegetables (Miean et al., 2001). 
apigenin has anti-inflammatory, anticancer 
oares et al., 2006, Singh et al., 2004, 
fruits 
cells is the reactivation of the reverse-
the expression and, therefore, the activity 
is very low or undetectable in normal CBIIS. LU et al. (2011) observed that the 
expression of telomerase appeared to be slightly higher in tumours with longer 
telomeres as well as in larger tumours or aggressive diseases. However, a few 
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